Rare Diseases: Economic Evaluation and Policy Considerations
- 28 October 2024
- journal article
- editorial
- Published by Elsevier in Value in Health
- Vol. 27 (12) , 1635-1636
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan DrugsValue in Health, 2024
- Evidence Quality and Health Technology Assessment Outcomes in Reappraisals of Drugs for Rare Diseases in GermanyValue in Health, 2024
- Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case StudyValue in Health, 2024
- Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous AltruismValue in Health, 2024
- Toward Patient-Centered Drug Approval for Treatment of Rare DiseasesValue in Health, 2024
- Orphan drugs policies: a suitable case for treatmentThe European Journal of Health Economics, 2014
- Orphan drugs: the regulatory environmentDrug Discovery Today, 2013
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67BMJ, 2010
- Orphan drugs and the NHS: should we value rarity?BMJ, 2005
- Why health equity?Health Economics, 2002